Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH31565D
  • |
  • Pages: 146
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, cardiovascular, central nervous systems, infectious disease, oncology, anesthesia and others. Mylan sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company has research and development facilities in the US, Canada, the UK, Ireland, Italy, Germany, India and Japan. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Mylan NV, Medical Devices Deals, 2011 to YTD 2017 13

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Mylan NV, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 19

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 20

Teva Pharma May Divest its Assets 21

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 22

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 24

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 26

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 27

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For USD30 Million 28

Rottapharm|Madaus Acquires Zyma Brands 29

Meda Acquires OTC Sleep Aid Product, MidNite 30

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For USD33 Million 31

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD95 Million 32

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 34

Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For USD348 Million 35

Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 36

Meda Completes Acquisition Of Global Rights To Elidel From Novartis For USD420 Million 37

Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 38

Private Equity 39

Riverside Acquires Euromed from Meda for USD86.7 Million 39

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 40

Partnerships 42

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 42

Mabion Enters into Distribution Agreement with Mylan 43

Pulmatrix Enters into Co-Development Agreement with Mylan 44

AB-Biotics Enters into Distribution Agreement with Mylan 45

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 46

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 46

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 47

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 48

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 49

Meda Expands Co-Development Agreement With Cipla For Dymista 50

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 51

Agila Specialties Forms Joint Venture With Jamp Pharma 52

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 52

Matrix Labs Plans Co-Marketing Agreement For 100 Products 53

Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 54

Licensing Agreements 55

Mylan Enters into Licensing Agreement with Genentech and Roche 55

Mylan Enters into Licensing Agreement with Medicines Patent Pool 56

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 56

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 57

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 58

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 59

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 59

Gilead Sciences Expands Licensing Agreement with Mylan Labs 61

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 62

Gilead Sciences Enters into Licensing Agreement with Mylan Labs 63

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 64

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 65

Mylan Enters Into Licensing Agreement With Orion for Stalevo 66

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 66

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 67

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 68

Moberg Pharma Amends Licensing Agreement with Meda 69

Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 70

Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 71

Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 73

Meda Amends Licensing Agreement With Medivir For Xerese 74

Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 75

Equity Offering 76

Abbott Prices Public Offering of Shares of Mylan for USD2 Billion 76

Meda to Raise USD278.7 Million in Rights Offering 77

Rottapharm Withdraws IPO for USD614.7 Million 79

Debt Offering 80

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 80

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 80

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 81

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 82

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 83

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 84

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 84

Mylan Completes Public Offering Of Notes Due 2019 For USD500 Million 85

Mylan Completes Public Offering Of Notes Due 2043 For USD500 Million 86

Mylan Completes Public Offering Of Notes Due 2016 For USD500 Million 88

Mylan Completes Public Offering Of Notes Due 2023 For USD500 Million 89

Mylan Completes Private Placement Of Notes Due 2018 For USD650 Million 90

Mylan Completes Private Placement Of Notes Due 2016 For USD500 Million 91

Meda Prices Public Offering Of Notes Due 2016 For USD62 Million 92

Meda Prices Public Offering Of Notes Due 2018 For USD92.4 Million 92

Mylan Completes Private Placement Of Notes Due 2023 For USD750 Million 93

Acquisition 94

Mylan Acquires Meda for USD9.9 Billion 94

Teva Pharma, Mylan May Acquire Teut|Pfizer 96

Meda Acquires Rottapharm from Fidim for USD3 Billion 98

Fidim Acquires Rottapharm Biotech from Rottapharm 99

Meda Acquires ZpearPoint, Dental Products Provider 100

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To USD1.75 Billion 100

Mylan Rumored To Acquire Bafna Pharma 103

Meda Completes Acquisition Of Acton Pharma For Up To USD200 Million 104

Mylan Acquires Synerx Pharma, Generic Maker 105

Meda Completes Acquisition Of Antula From Healthcare Brands 105

Mylan NV-Key Competitors 107

Key Employees 108

Locations And Subsidiaries 109

Head Office 109

Other Locations & Subsidiaries 109

Recent Developments 116

Financial Announcements 116

May 10, 2017: Mylan Reports First Quarter 2017 Results 116

Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 118

Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 120

Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 124

May 03, 2016: Mylan Reports Strong First Quarter 2016 Earnings Results Including Total Revenues Up 17% 127

Feb 10, 2016: Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30 129

Corporate Communications 133

May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 133

Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 134

Dec 20, 2016: Mylan launches authorised generic version of EpiPen 135

Jun 23, 2016: Mylan Donates 1 Million to the Princess Mxima Center for Pediatric Oncology 136

May 03, 2016: Mylan Names Kenneth Parks Chief Financial Officer 137

Feb 22, 2016: Mylan Appoints Anthony Mauro Chief Commercial Officer 138

Feb 22, 2016: Mylan CEO Heather Bresch Elected Chair of Generic Pharmaceutical Association 139

Jan 08, 2016: Mylan CFO John Sheehan to Retire as of April 1, 2016 140

Legal and Regulatory 141

Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated 141

Product News 143

Nov 29, 2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis 143

Product Approvals 144

Jan 11, 2016: Mylan Confirms FDA Submission of ANDA for Generic Advair Diskus 144

Other Significant Developments 145

Mar 08, 2016: Mylan Health Hackathon to Focus on Delivering Better Health for a Better World 145

Appendix 146

Methodology 146

About GlobalData 146

Contact Us 146

Disclaimer 146

List of Figures

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Mylan NV, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

Mylan NV, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mylan NV, Deals By Therapy Area, 2011 to YTD 2017 11

Mylan NV, Medical Devices Deals, 2011 to YTD 2017 13

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 19

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 20

Teva Pharma May Divest its Assets 21

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 22

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 24

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 26

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 27

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For USD30 Million 28

Rottapharm|Madaus Acquires Zyma Brands 29

Meda Acquires OTC Sleep Aid Product, MidNite 30

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For USD33 Million 31

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For USD95 Million 32

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 34

Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For USD348 Million 35

Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 36

Meda Completes Acquisition Of Global Rights To Elidel From Novartis For USD420 Million 37

Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 38

Riverside Acquires Euromed from Meda for USD86.7 Million 39

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 40

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 42

Mabion Enters into Distribution Agreement with Mylan 43

Pulmatrix Enters into Co-Development Agreement with Mylan 44

AB-Biotics Enters into Distribution Agreement with Mylan 45

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 46

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 46

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 47

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 48

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 49

Meda Expands Co-Development Agreement With Cipla For Dymista 50

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 51

Agila Specialties Forms Joint Venture With Jamp Pharma 52

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 52

Matrix Labs Plans Co-Marketing Agreement For 100 Products 53

Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 54

Mylan Enters into Licensing Agreement with Genentech and Roche 55

Mylan Enters into Licensing Agreement with Medicines Patent Pool 56

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 56

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 57

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 58

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 59

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 59

Gilead Sciences Expands Licensing Agreement with Mylan Labs 61

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 62

Gilead Sciences Enters into Licensing Agreement with Mylan Labs 63

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 64

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 65

Mylan Enters Into Licensing Agreement With Orion for Stalevo 66

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 66

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 67

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 68

Moberg Pharma Amends Licensing Agreement with Meda 69

Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 70

Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 71

Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 73

Meda Amends Licensing Agreement With Medivir For Xerese 74

Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 75

Abbott Prices Public Offering of Shares of Mylan for USD2 Billion 76

Meda to Raise USD278.7 Million in Rights Offering 77

Rottapharm Withdraws IPO for USD614.7 Million 79

Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 80

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 80

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 81

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 82

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 83

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 84

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 84

Mylan Completes Public Offering Of Notes Due 2019 For USD500 Million 85

Mylan Completes Public Offering Of Notes Due 2043 For USD500 Million 86

Mylan Completes Public Offering Of Notes Due 2016 For USD500 Million 88

Mylan Completes Public Offering Of Notes Due 2023 For USD500 Million 89

Mylan Completes Private Placement Of Notes Due 2018 For USD650 Million 90

Mylan Completes Private Placement Of Notes Due 2016 For USD500 Million 91

Meda Prices Public Offering Of Notes Due 2016 For USD62 Million 92

Meda Prices Public Offering Of Notes Due 2018 For USD92.4 Million 92

Mylan Completes Private Placement Of Notes Due 2023 For USD750 Million 93

Mylan Acquires Meda for USD9.9 Billion 94

Teva Pharma, Mylan May Acquire Teut|Pfizer 96

Meda Acquires Rottapharm from Fidim for USD3 Billion 98

Fidim Acquires Rottapharm Biotech from Rottapharm 99

Meda Acquires ZpearPoint, Dental Products Provider 100

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To USD1.75 Billion 100

Mylan Rumored To Acquire Bafna Pharma 103

Meda Completes Acquisition Of Acton Pharma For Up To USD200 Million 104

Mylan Acquires Synerx Pharma, Generic Maker 105

Meda Completes Acquisition Of Antula From Healthcare Brands 105

Mylan NV, Key Competitors 107

Mylan NV, Key Employees 108

Mylan NV, Other Locations 109

Mylan NV, Subsidiaries 110

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Mylan NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16235
Site License
USD 500 INR 32470
Corporate User License
USD 750 INR 48705

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com